Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
Appointed COO
Jasper Therapeutics, Inc. (AMHCU) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Investor presentation
Docs: "CORPORATE PRESENTATION, DATED OCTOBER 2023"
10/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria"
08/11/2023 8-K Quarterly results
Docs: "Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update"
06/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF",
"JASPER THERAPEUTICS, INC. AMENDED AND RESTATED 2022 INDUCEMENT EQUITY INCENTIVE PLAN"
06/02/2023 8-K Investor presentation
Docs: "CORPORATE PRESENTATION, DATED JUNE 2023"
04/14/2023 8-K Quarterly results
03/08/2023 8-K Quarterly results
Docs: "Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update"
01/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares REDWOOD CITY, Calif., January 27, 2023 – Jasper Therapeutics, Inc. , a biotechnology company focused on developing novel antibody therapies targeting c-Kit to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes as well as novel stem cell transplant conditioning regimes, announced today the closing of its previously announced underwritten public offering of 69,000,000 shares of its common stock, at a public offering price of $1.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 9,000,000 additional shares of common stock. The gross proce..."
01/25/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNDERWRITING AGREEMENT",
"OPINION OF PAUL HASTINGS LLP",
"Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock REDWOOD CITY, Calif., January 25, 2023 – Jasper Therapeutics, Inc. , a biotechnology company focused on developing novel antibody therapies targeting c-Kit to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes as well as novel stem cell transplant conditioning regimes, announced today the pricing of its underwritten public offering of 60,000,000 shares of its common stock. Each share of common stock will be sold at a public offering price of $1.50 per share, for gross proceeds of approximately $90 million, before deducting underwriting discounts and commissions and offering expenses. Jasper intends to use the net proceeds from the offering for ge..."
01/24/2023 8-K Investor presentation
Docs: "CORPORATE PRESENTATION, DATED JANUARY 2023"
01/19/2023 8-K Quarterly results
01/13/2023 8-K Quarterly results
01/10/2023 8-K Quarterly results
11/10/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
11/04/2022 8-K Quarterly results
08/12/2022 8-K Quarterly results
Docs: "Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update"
06/27/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/27/2022 8-K Investor presentation
Docs: "Jasper Therapeutics, Inc. Presentation (Preliminary Data from a Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning: Well-Tolerated, Facilitates Chimerism and Clearance of Minimal Residual Disease in Older Adults with MDS/AML Undergoing Allogeneic HCT (NCT#04429191))"
03/21/2022 8-K Appointed COO
Docs: "Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team"
03/18/2022 8-K Quarterly results
Docs: "Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update"
03/16/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "JASPER THERAPEUTICS, INC. 2022 INDUCEMENT EQUITY INCENTIVE PLAN"
03/16/2022 8-K Investor presentation
Docs: "JASPER THERAPEUTICS, INC. INVESTOR PRESENTATION"
03/11/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
02/24/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "JSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic syndrome or acute myeloid leukemia in Ph1b dose expansion study"
11/12/2021 8-K Quarterly results
Docs: "Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update"
10/29/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "JASPER THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY"
09/29/2021 8-K Quarterly results
09/22/2021 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits  Interac...
Docs: "Amplitude Healthcare Acquisition Corporation Announces Shareholder Approval of Business Combination with Jasper Therapeutics, Inc."
09/20/2021 8-K Quarterly results
09/09/2021 8-K Quarterly results
05/18/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy